Doctoral Candidate 5
Development and validation of novel gene editing delivery vehicles ‘nanoblades’ retargeted to T cells and hematopoietic stem cells
Host institution: INSERM, France
Supervisory team: Prof. Els Verhoeyen (INSERM, Université Côte d’Azur), Prof. Rik Gijsbers (KU Leuven), Dr; Otto-Wilhelm Merten (Miltenyi Biotech)
This project is situated in the field of novel modalities to deliver gene therapy. The objectives are: (1) To pseudotype nanoblades (gene editing delivery vehicles) using novel paramyxovirus glycoproteins (gps) in order to redirect them to T Cells or HSCs. (2) To evaluate the targeting efficiency of these nanoblades in vitro. (3) Up-scaling and improving the production of the novel nanoblades. (4) in vivo evaluation of novel nanoblades in patient cells and humanised mice. The project will involve wet lab work including viral vector production and testing in relevant animal models.
A successful project will result in: (1) Nanoblades efficiently targeting T cells and HSCs. (2) Optimised production protocol for retargeted nanoblades.
Enrolment in Doctoral School: Université Côte d’Azur (Nice)
KU Leuven, Belgium (M19-22): Upscaling and QC of novel nanoblade production;
University of Tübingen, Germany (28-29): evaluation of nanoblades in OoC models;
Miltenyi Biotech, Germany (EP, M38): Working in GMP environments.
You hold a master’s degree in biomedical sciences, biotechnology or a related field.
You are ambitious, well organized and have excellent communication skills.
You are proficient in English both verbal and written
You have the ability to work independently and have a critical mindset.
You are an enthusiastic and motivated person, eager to participate in network wide training events, international travel and public awareness activities.
Willingness to travel
SKILLS AND EXPERTISE
Solid knowledge of virology/vectorology
Good understanding of gene editing strategies